Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Depomed makes management promotions
Mr Vargas joined Depomed as vice president of business development in December 2002, while Ms Cameron joined Depomed as controller in July 2007 and was named interim principal
Mr Vargas joined Depomed as vice president of business development in December 2002, while Ms Cameron joined Depomed as controller in July 2007 and was named interim principal
The investigational new drug applications (INDs) signify the company’s intentions to begin clinical investigation for CB-182,804, a Cubist-discovered, potent, cidal, IV lipopeptide in development as therapy for the
“Our second quarter results demonstrate the strength of our business model with its strong recurring revenue and cash flow,” stated Gioacchino De Chirico, president and chief executive officer.
Through its subsidiary UPS Supply Chain Solutions, United Parcel Service (UPS) said that it has assumed control of two key Merck distribution centers, which provide Merck with temperature-sensitive
In this role, Mr Mengler will be responsible for expanding the company’s generic business by growing capability in the US market while driving global opportunities. Mr Mengler comes
Mr Byle is presently vice-president of technology for Dockwise, a public, international company, where he is in charge of its R&D program and intellectual property portfolio. Michael Cohen,
Bayer Schering Pharma has programs for cancer, cardiovascular diseases and gynecological therapies and GeneGo has good coverage of these diseases and others, said GeneGo. GeneGo is also in
This agreement will give Centocor and its Ortho Biotech Oncology R&D division affiliates the opportunity to discover and develop novel small molecule inhibitors of the fatty acid biosynthesis
Dr Egeler is a pediatric bone marrow transplantation physician and an internationally recognized authority in pediatric hemato-oncology. He brings to Kiadis Pharma over more than 20 years of
The company’s board of directors has approved a plan of complete liquidation and dissolution of the company (the plan), subject to shareholder approval. The company intends to hold